SOUTH SAN FRANCISCO, Calif., March 20, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today that the US Patent and Trademark Office issued U.S. Patent No. 8,397,859, covering certain benzosuberene-based compounds, including the analogues referred to as KGP18 and KGP156 that are currently in preclinical development. The patent also covers methods of using those compounds to inhibit tubulin polymerization, to reduce blood flow to a tumor, or to restrain, slow, stop or reverse progression of a tumor.
These compounds are the product of OXiGENE's ongoing collaboration with Kevin G. Pinney, Ph.D. and Mary Lynn Trawick, Ph.D.at Baylor University to identify inhibitors of tubulin polymerization as vascular targeting agents and as back-up compounds to OXiGENE's combretastatin A-4P (ZYBRESTAT ®) and OXi4503. Recently, the focus of this collaboration has centered on the development of novel antiproliferative agents (benzosuberenes) and anti-invasive molecules (cathepsin L inhibitors). OXiGENE has an exclusive license to the worldwide rights to all of the compounds that result from this collaboration.
"The issuance of the patent covering benzosuberenes is an important achievement for OXiGENE that enhances the value of our anticancer portfolio for potential pharmaceutical partners and investors," said Peter J. Langecker, M.D., Ph.D., OXiGENE's Chief Executive Officer. "We believe that this exciting new class of compounds has the potential to enhance treatment options for oncologists and patients with cancer. This work also demonstrates the continued productivity of our collaboration with Baylor University.""This benzosuberene series of molecules are among the most potent antiproliferative agents identified to date in our laboratories, and we believe this exceptional potency coupled with their antivascular activity make these compounds potentially well-suited for selective delivery strategies, including their use as payloads for antibody-directed therapy," said Dr. Pinney, Professor of Chemistry at Baylor University.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV